Journal Article

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

Sorgho, Hermann, Griggs, Allison, Abdulla, Salim, Aide, Pedro, Agbenyega, Tsiri, Connolly, Kristen M, Dobaño, Carlota, Adjei, Samuel, Birkett, Ashley J, Njuguna, Patricia, Greenwood, Brian, Leach, Amanda, Gesase, Samwel, Yu, Qing, Kariuki, Simon, Gilbert, Peter B, Agnandji, Selidji T, Bejon, Philip, Grimsby, Jonna, Otieno, Kephas, Lennon, Niall J, Otieno, Lucas, Tinto, Halidou, Park, Daniel J, Aponte, John J, Lapierre, Didier, Ansong, Daniel, Lell, Bertrand, Martinson, Francis, Ockenhouse, Christian F, Hamel, Mary J, Volkman, Sarah K, Lusingu, John, Hoffman, Irving, Sacarlal, Jahit, Neafsey, Daniel E, Ryan, Elizabeth M, Asante, Kwaku Poku, Juraska, Michal, Owusu-Agyei, Seth, Sogoloff, Brian, Bruls, Myriam, Wirth, Dyann F, D’Alessandro, Umberto, Robbins, Dana, Kremsner, Peter G, Pellé, Karell, Theander, Thor, Tanner, Marcel, Kamthunzi, Portia, Russ, Carsten, Birren, Bruce W, Otieno, Walter, Anderson, Scott, Bedford, Trevor, Moss, Eli L, Valea, Innocent, Ogutu, Bernhards Ragama, Benkeser, David, Lievens, Marc, Molel, Jackson T, Valim, Clarissa, Marsh, Kevin

2015

Overview

There is a tremendous need for a malaria vaccine. By means of a sieve analysis, the RTS,S/AS01 candidate vaccine, which is in advanced clinical development, was shown to have improved vaccine efficacy against genetically matched versus mismatched infecting malaria strains. Malaria induces substantial morbidity and mortality worldwide 1 and has proved to be a challenge for vaccine-development efforts. The recently renewed effort to control, eliminate, and hopefully eradicate malaria will have a greater likelihood of success if a vaccine can be combined with other intervention methods, such as drug-administration campaigns and insect-vector control. 2 , 3 The most advanced candidate vaccine for protection against Plasmodium falciparum malaria infection, RTS,S/AS01, is a monovalent recombinant protein vaccine that targets a fragment of the circumsporozoite protein parasite antigen. RTS,S/AS01 was evaluated in a large randomized, controlled, phase 3 trial, conducted at 11 study sites in Africa . . .

• Publisher: Massachusetts Medical Society
• Subject: Africa / Alleles / Amino acids / Antigens / Children / Circumsporozoite protein / DNA sequencing / Female / Genetic diversity / Genetic Variation / Humans / Infant / Infants / Malaria / Malaria Vaccines - immunology / Malaria, Falciparum - immunology / Malaria, Falciparum - parasitology / Malaria, Falciparum - prevention & control / Male / Parasites / Plasmodium falciparum / Plasmodium falciparum - genetics / Polymerase chain reaction / Population genetics / Protein C / Proteins / Treatment Outcome / Vaccination / Vaccine efficacy / Vaccines